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Abstract: Familial Mediterranean fever (FMF) is an autosomal recessive hereditary disease which 
is characterized by recurrent attacks of fever and peritonitis, pleuritis, arthritis, or erysipelas
skin disease. As such, FMF is a prototype of autoinflammatory dis
to acute inflammatory episodes. Systemic inflammation 
factors, and decrease natural anticoagulants and fibrinolytic activity. Therefore, it is anticipated to 
see  more  thrombotic  events  among  FMF  patients  compared  with  healthy  subjects.  However, 
reviewing  the current available  literature and  based  upon  our  personal experience, thrombotic 
events related purely to FMF are very rare. Possible explanation for this discrepancy is that along
with the procoagulant activity during FMF acute attacks, anticoagulant and fibrinolytic changes 
are also taking place. Colchicine which is the treatment of choice in FMF may also play a role in 
reducing inflammation thereby decreasing hypercoagulability.
Introduction: Familial Mediterranean fever (FMF) is 
an  autosomal  recessive  hereditary  disease  which  is 
characterized  by  recurrent  attacks  of  fever  and 
peritonitis,  pleuritis,  arthritis,  or  erysipelas
disease.
1 The gene associated with FMF (MEFV) was 
isolated  in  1997  by  two  independent  groups.
encodes  a  781  amino  acid  protein  named  pyrin
marenostrin,  which  suppresses  inflammation  via 
interaction with peptides and cytokines involved in this 
process.  Mutations  in  MEFV  affect  pyrin  function, 
decreasing  its  suppressor  effect  of  inflammation 
leading to the eruption of the characteristic acute attack 
of  FMF.
4 Thus,  FMF  is  a  prototype  of 
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Familial Mediterranean fever (FMF) is an autosomal recessive hereditary disease which 
is characterized by recurrent attacks of fever and peritonitis, pleuritis, arthritis, or erysipelas
skin disease. As such, FMF is a prototype of autoinflammatory diseases where genetic changes lead 
to acute inflammatory episodes. Systemic inflammation – in general - may increase procoagulant 
factors, and decrease natural anticoagulants and fibrinolytic activity. Therefore, it is anticipated to 
ts  among  FMF  patients  compared  with  healthy  subjects.  However, 
reviewing  the current available  literature and  based  upon  our  personal experience, thrombotic 
events related purely to FMF are very rare. Possible explanation for this discrepancy is that along
with the procoagulant activity during FMF acute attacks, anticoagulant and fibrinolytic changes 
are also taking place. Colchicine which is the treatment of choice in FMF may also play a role in 
reducing inflammation thereby decreasing hypercoagulability.
Familial Mediterranean fever (FMF) is 
an  autosomal  recessive  hereditary  disease  which  is 
characterized  by  recurrent  attacks  of  fever  and 
pleuritis,  arthritis,  or  erysipelas-like  skin 
The gene associated with FMF (MEFV) was 
isolated  in  1997  by  two  independent  groups.
2,3 It 
encodes  a  781  amino  acid  protein  named  pyrin-
marenostrin,  which  suppresses  inflammation  via 
eptides and cytokines involved in this 
process.  Mutations  in  MEFV  affect  pyrin  function, 
decreasing  its  suppressor  effect  of  inflammation 
leading to the eruption of the characteristic acute attack 
Thus,  FMF  is  a  prototype  of 
autoinflammatory diseases where genetic changes lead 
to acute inflammatory episodes.
Hypercoagulability  is  a  laboratory  phenotype 
whereby  in  vivo activation  of  clotting,  fibrinolysis, 
endothelial cells and platelets are identified 
specialized  clotting  techniques  and  by  specific 
antibodies directed at biomarkers of clotting activation 
and damaged vasculature.
5 Hypercoagulability may be 
provoked  by  inherited  or  acquired  thrombophilia  as 
well  as  by  sepsis,  surgery,  blood  stasis  and
inflammation.
In  general,  systemic  inflammation  may  increase 
procoagulant  factors  and  decrease  natural 
anticoagulants and fibrinolytic activity.
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eases where genetic changes lead 
may increase procoagulant 
factors, and decrease natural anticoagulants and fibrinolytic activity. Therefore, it is anticipated to 
ts  among  FMF  patients  compared  with  healthy  subjects.  However, 
reviewing  the current available  literature and  based  upon  our  personal experience, thrombotic 
events related purely to FMF are very rare. Possible explanation for this discrepancy is that along
with the procoagulant activity during FMF acute attacks, anticoagulant and fibrinolytic changes 
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ses where genetic changes lead 
to acute inflammatory episodes.
Hypercoagulability  is  a  laboratory  phenotype 
activation  of  clotting,  fibrinolysis, 
endothelial cells and platelets are identified in vitro by 
specialized  clotting  techniques  and  by  specific 
antibodies directed at biomarkers of clotting activation 
Hypercoagulability may be 
provoked  by  inherited  or  acquired  thrombophilia  as 
well  as  by  sepsis,  surgery,  blood  stasis  and
In  general,  systemic  inflammation  may  increase 
procoagulant  factors  and  decrease  natural 
anticoagulants and fibrinolytic activity.
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many  cytokines  involved  in  inflammation  are  also 
known  to  trigger  coagulation.
7 As  a  prototype 
inflammatory  disease  in  FMF,  levels  of  acute  phase 
reactants and cytokines, such as CRP, IL-1, IL-6 and 
IL-8,  are  significantly  elevated  during  and  between 
attacks.
8 Therefore, one expects to see more thrombotic 
events  among  these  patients  compared  with  healthy 
subjects.  However,  reviewing  the  current  available 
literature and based on our personal experience in our 
clinic,  the  impression  is  that  events  of  thrombosis 
related purely to FMF are very rare. Case reports about 
thrombotic  events  in  FMF  are  almost  always  on 
patients with renal disease, amyloidosis and proteinuria 
or other concomitant thrombophilias.
9-11
We  review  the  available  literature  about 
coagulability  in  FMF  and  try  to  understand  why 
thrombotic events are  rare in  this  disease despite its 
being a typical inflammatory disease.
Fibrinogen: Fibrinogen contributes to thrombosis risk 
in  different  ways  and  is  important  in  regulating 
inflammatory  response.
12 Significant  differences  in 
levels  of  fibrinogen  among  FMF  patients  during  an 
attack, patients free of attack and controls were found 
in one study, where the highest levels were found in 
patients during attacks, medium levels in patients free 
of attack and the lowest levels in healthy controls.
13 In 
another study, no statistically significant difference in 
serum fibrinogen was found in attack-free periods of 
FMF patients compared with healthy controls, but the 
levels were remarkably higher  in  patients during the 
acute attacks.
14 Thus, in FMF - especially during acute 
attacks - levels of fibrinogen can be high. Since this 
protein is an important precursor for fibrin, which is 
essential for the final clotting pathway, this situation 
may theoretically enhance coagulation.
Prothrombin Time and Thrombin Time: Thrombin, 
formed  by  activation  of  the  coagulation  cascade,  is 
essential  to  promote  hemostasis  but  also  stimulates 
several  cell  functions,  including  chemotaxis  and 
mitogenesis. Thrombin not only converts fibrinogen to 
fibrin, it also acts as a proinflammatory agent, resulting 
in  a  positive  feedback  loop  of  the  inflammo-
coagulatory response.
15 Thrombin time (TT) as well as 
prothrombin time  (PT)  were shortened in  attack-free 
periods  in  FMF  patients  compared  with  controls, 
suggesting  an  increased  baseline  inflammatory 
condition  with  an  increased  state  of 
hypercoagulabilty.
14 Contradictory  results  were 
reported in another study where the PT in FMF patients 
during  an  attack  period  was  significantly  prolonged 
compared with patients during their attack-free periods 
or with a healthy control group. This observation was 
accompanied  by  increased  levels  of  the  acute  phase 
reactants  suggesting  discordance  between  these  two 
processes - thrombosis and inflammation. However, it 
should be emphasized that in the later study, PT levels 
varied  largely  among  the  patients  of  all  groups, 
especially  in  the  attack  group.
13 These  contradictory 
results should be resolved in additional studies. In the 
meantime,  the  role  of  thrombin  as  a  procoagulant 
factor in FMF should await further investigation. 
D-dimer: D-dimer is formed as a result of the plasmin-
mediated,  proteolytic  degradation  of  cross-linked 
fibrin.
16 In general, D-dimer levels are increased during 
any clinical condition where both clot formation and 
subsequent fibrinolysis take place.
17 Elevated D-dimer
levels  were  found  in  FMF  patients  during  the  acute 
attacks. Between the attacks, D-dimer levels were still 
elevated  compared with healthy controls but  far less 
than those in patients with acute attack.
13 However, in 
another  study,  D-dimer  levels  between  controls  and 
attack-free  patients  were  found  to  be  similar, 
suggesting that these components are elevated mainly 
during acute FMF attacks.
14 Thus, increased D-dimer 
may indicate a fibrinolytic process taking place during 
the  acute  attack or  an  expression  of increased  acute 
phase reactants due to the inflammatory episode.
Plasminogen  Activator  Inhibitor  1: Plasminogen 
activator inhibitor 1 (PAI-1) is produced by endothelial 
cells and inhibits fibrinolysis. PAI-1 is also considered 
to be one of the markers of endothelial dysfunction. An 
increase in PAI-1 causes hypofibrinolysis and results in 
a  hypercoagulable  state.
18 In  a  single  study  which 
measured  levels  of  PAI-1  among  FMF  patients, 
significant low levels were found during the attack-free 
period compared with the acute attack period.
13 This 
observation  suggests  that  during  the  acute  event 
elevated PAI-1 may increase coagulability. However, 
the  exact  role  of  this  peptide  in  predisposing 
thrombosis in FMF should await further studies. 
Tissue  Plasminogen  Activator: Tissue  plasminogen 
activator (tPA) is the trigger of the fibrinolytic activity, 
and fibrinolytic pathways must be activated along with 
the coagulation activation.
19 Significantly higher levels 
of tPA were found in FMF patients during attacks than 
in controls, and statistically insignificant higher levels 
were  found  in  attack-free  periods  in  FMF  patients 
compared  with  controls.
13 This  observation  may 
indicate that during inflammation there is a persistent 
fibrinolytic activity which counterbalances coagulation 
during  the  ongoing  inflammation  of  FMF  attacks.
6
Thus,  tPA  may  serve  as  a  counter  regulator  of  the 
previous  components  which  contribute  to  the 
procoagulant status. Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
P-selectin: P-selectin  is  a  marker  of  thrombocyte 
activation.  Serum  levels  of  P-selectin  did  not  differ 
significantly between FMF patients during the attack or 
attack-free  periods.  However,  these  levels  were 
significantly  lower  in  both  patient  groups  compared 
with controls. Again, the low levels of P-selectin might 
reflect  a  response mechanism  to  counteract  the 
hypercoagulable state in  FMF patients. Nevertheless, 
since the blood sampling was late (in the FMF attacks), 
one should be cautious in drawing firm conclusions.
13
Protein C Activity: Activated  protein C (APC) is a 
natural  anticoagulant  that  plays  an  important  role  in 
coagulation  homeostasis  by  inactivating  the 
procoagulation factors Va and VIIIa. In addition to its 
anticoagulation functions, APC also has cytoprotective 
effects such as anti-inflammatory, anti-apoptotic, and 
endothelial barrier protection.
20
Protein C activity decreased in FMF patients during 
attack-free  periods  compared  with  healthy  controls. 
This finding may indicate the problem in suppressing 
inflammatory response through the protein C pathway 
in the acute attack.
14 Furthermore, reduction of APC 
may increase hypercoagulability in FMF patients.
Fibronectin and Thrombospondin: Fibronectin (FN) 
and  thrombospondin  (TSP)  are  extracellular  matrix 
proteins.  Fibronectin,  apart  from  being  an  adhesive 
solid phase element, has many different roles in wound 
healing and cellular adhesion. More recently, FN has 
emerged as a player in platelet thrombus formation and 
diseases associated with thrombosis, including vascular 
remodeling,  atherosclerosis  and  cardiac  repair 
following myocardial infarction.
21
Thrombospondin  is  a  glycoprotein  that  interacts 
with  a  wide variety  of  molecules, including heparin, 
fibrin,  fibrinogen,  platelet  cell  membrane  receptors, 
collagen, and fibronectin. It also plays a role in platelet 
aggregation, tumor metastasis, vascular smooth muscle 
growth and tissue repair in skeletal muscle following 
crush injury. As such, it is another extracellular matrix 
product  which  is  primarily  found  in  the  granules  of 
thrombocytes. However, it can also be synthesized and 
secreted  by  many  inflammatory  cells,  including 
neutrophils. Both fibronectin and thrombospodin may 
play a role in promoting hypercoagulability in addition 
to  their  role  in  inflammation.  Plasma  FN  and  TSP 
levels  during  acute  FMF  attacks  were  significantly 
higher  than  after  resolution  of  the  acute  attacks.  In 
addition,  significant  correlations  were  observed 
between both FN and TSP levels and CRP and WBC 
counts in two different studies.
13,22 On one hand, the 
above  findings  may  suggest  that  FN  and  TSP  are 
factors potentially able to enhance hypercoagulability 
during the acute attacks. On the other hand, their high 
correlation with acute phase reactants may reflect their 
important roles in the inflammatory process during the 
attacks  rather  than  their  procoagulant  effect  on  this 
condition.
vW Factor and Factor VIII: Von Willebrand factor 
(vWF)  is  a  large  multimeric  glycoprotein present  in 
blood  plasma and  produced  constitutively  in 
endothelium,  megakaryocytes and  subendothelial 
connective tissue.
23 Its primary function is binding to 
other  proteins,  in  particular  Factor  VIII,  and  it  is 
important  in  platelet  adhesion  to  wound  sites.
Endothelial damage due to inflammation  triggers the 
coagulation cascade. In a study where levels of factors 
VIII and vWF were measured during FMF attacks and 
during  free-attack  periods  no  difference  was  found. 
Furthermore,  these  results  did  not  differ  from  those 
found  in  healthy  controls.
13 It  seems  that  these  two 
factors do not play any role either in inflammation or in 
coagulation in FMF. 
Thrombocytes and MPV: Although thrombocytes can 
be  used  as  a  marker  for  acute  phase  reactants,  and 
MPV levels may be the first to increase in response to 
inflammation, no differences in thrombocyte count and 
MPV were found between FMF patients and controls.
13
Other  Factors: Increased  levels  of  prothrombin 
fragments F1+2 were found in attack-free  periods in 
FMF  patients  compared  with  healthy  controls.  No 
differences were found in levels of activated protein C 
resistance  (APCR),  antithrombin or  anti  cardiolipin 
antibodies in FMF patients and controls.
14
Discussion: Many  studies  have  shown  that  in  FMF 
inflammation exists not only during the acute attacks, 
but  also  between  attacks.  Increased  CRP  and  serum 
amyloid A  (SAA)  and  elevated  cytokines  levels 
between  attacks  reflect  an  ongoing  sub-clinical 
inflammation during these periods.
24 The coagulation 
system is closely related to the inflammatory system 
and  it  is  known  that  systemic  inflammation  and 
elevated  cytokines  are  capable  of  triggering 
coagulation.
The  above-mentioned  studies  which  dealt  with 
coagulability changes in FMF patients shed some light 
on  the  association  between  coagulation  and 
inflammation during the acute attacks and in between 
them. Most of these investigations show that in FMF -
especially during the acute attacks - some parameters 
of  coagulation  are  abnormal.  This  theoretically  may 
increase the risk for thrombotic events in FMF patients. 
Nevertheless,  reviewing  the  English  literature  for 
thrombotic events in these patients disclosed very few 
case reports. A single case report presented a child with Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
FMF  who  experienced  a  stroke.  An  extensive 
thrombophilia  work-up  revealed  that  the  patient  had 
concomitant  multiple  inherited  and  acquired  risk 
factors for  thrombosis.
9 In other  cases of thrombotic 
events in FMF patients, concomitant renal disease or 
amyloidosis  was  also  found.
10 It  seems  that  the 
presence  of  proteinuria  in  these  cases  served  as  a 
second  hypercoagulable  hit,  due  to  deficiency  of 
antithrombin  causing  development  of  thrombosis.  A 
recent study reported two FMF patients who developed 
Budd  Chiari  syndrome.  Thorough  investigation 
revealed that one of the patients was homozygous for 
MTHFR mutation (677C>T), whereas the other carried 
a single mutation in the factor V Leiden (FVL).
11 The 
authors suggested that "FMF should be regarded as a 
possible  additional  thrombotic  risk  factor  in  such 
cases".
Following  the  identification  and  isolation  of  the 
MEFV  gene,  several  studies  searched  for  a  possible 
role of MEFV mutations in hypercoagulability. In fact 
a study by Rabinovitch et al. found that in patients with 
Behcet's  disease  who  carried  the  MEFV  mutation 
M694V,  there  were  more  vascular  and  thrombotic 
events compared with BD patients who did not carry 
this mutation.
25 Since Behcet's disease is characterized 
by thrombotic events due to endothelitis and vasculitis, 
the  question  is  raised  as  to  the  exact  role  or 
contribution  of  FMF  and  MEFV  mutations  in  these 
patients who are a priori prone to develop thrombosis.
The  above  cases  show  that  FMF  alone  is  not  a 
direct cause for thrombosis and, in fact, in all the above 
cases there was an additional procoagulant background 
which led to the thrombotic complication.
This observation raises the question regarding the 
explanation for the scarce reports on thrombotic events 
in patients with FMF only.
One possible answer could be that along with the 
ongoing  inflammation  in  FMF  leading  to  the 
procoagulant activity during the  acute attacks and in 
between them, anticoagulant and fibrinolytic changes 
are  also  taking  place. Thus,  there  may  be  a  balance 
between  coagulation  and  fibrinolysis  in  vivo.  The 
higher  than  normal  tPA  levels  during  attack-free 
periods in FMF patients may indicate the importance of 
such  persistence  of  the  fibrinolytic  activity  for  the 
balance of ongoing inflammation and coagulation and 
may  be  the  key  for  the  prevention  of  future 
thrombosis.
6 The  changes  in  P-selectin  may  play  a 
similar anticoagulant role.
13
An  additional  possible  explanation  is  that  all  the 
above  factors  which  are  associated  with 
hypercoagulability in fact also serve as inflammatory 
components. It may well be that during the acute attack 
of FMF they are consumed or used for the purpose of 
inflammation so that nothing is left for their role in the 
coagulation  pathway.  It  seems  that  during  an  acute 
FMF attack the inflammatory process overcomes the 
coagulation process. 
Another question which might be raised is whether 
colchicine  – which  is  taken  continuously  by  FMF 
patients - has any role in the coagulation pathway.
The observation that the highest levels of D-dimer 
were found during attacks in FMF patients who did not 
use  colchicine  suggests  that  colchicine  decreases 
fibrinolytic  activity  by  suppressing  inflammation. 
Colchicine treatment is known to reduce the frequency 
and intensity of attacks in FMF, and it apparently also 
lowers the level of circulating fibrin, thereby reducing 
coagulation  and  later  fibrinolysis.
13 Colchicine 
treatment  also  lowers  levels  of  soluable  E- and  L-
selectin in FMF and Behcet's patients (26, 27) and  was 
shown  to  diminish    the  qualitative  expression  of  E-
selectin  on  endothelium,  and  the  quantitative 
expression of of L-selectin on neutrophils.
28
In  summary, the  studies  reviewed  herein  have  just 
started revealing the procoagulant activity in FMF and 
its relationship to the acute attacks. Although it seems 
that  coagulability  is  increased  and  enhanced  during 
these attacks and in between them, the patients do not 
experience increased thrombotic events. 
Yet the current studies are few and in some cases 
the results are conflicting. Larger studies are needed to 
confirm  the  observations  about  the  changes  in 
coagulation in FMF patients. Furthermore, large case
age matched control prospective studies are require to 
disclose  the  potential  association  of  coagulation 
parameters with MEFV mutations.
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